Abstract
Many effective strategies have been developed in order to inhibit the hydrodechlorination in the selective hydrogenation of chloronitrobenzenes to chloroanilines which are important intermediates in the chemistry and industry of dyes, herbicides, pesticides and medicines. However, hydrogenolysis of the carbon-halogen bond as a defect of the hydrogenation process could not be avoided completely over the metal catalysts reported previously, especially at complete conversion of the substrates. Recently we overcame this problem by the invention of nanocomposite catalysts composed of noble metal nanoclusters and inorganic semiconductor nanoparticles. Over these nanocomposite catalysts, the hydrodechlorination of ortho-chloroaniline was completely suppressed even at 100% conversion of ortho-chloronitrobenzene. In this review, we deal with the great efforts and remarkable contributions of different authors during the long exploration for the solutions of this hard obstacle. Stress is placed on supported metal catalysts and polymer-protected metal nanoclusters or colloid catalysts.
Keywords: hydrogenation, bromonitrobenzenes (BNB), Bimetallic Catalysts, colloids, Metal Complexes
Current Organic Chemistry
Title: Selective Hydrogenation of Aromatic Chloronitro Compounds
Volume: 11 Issue: 3
Author(s): Xiaodong Wang, Minghui Liang, Junling Zhang and Yuan Wang
Affiliation:
Keywords: hydrogenation, bromonitrobenzenes (BNB), Bimetallic Catalysts, colloids, Metal Complexes
Abstract: Many effective strategies have been developed in order to inhibit the hydrodechlorination in the selective hydrogenation of chloronitrobenzenes to chloroanilines which are important intermediates in the chemistry and industry of dyes, herbicides, pesticides and medicines. However, hydrogenolysis of the carbon-halogen bond as a defect of the hydrogenation process could not be avoided completely over the metal catalysts reported previously, especially at complete conversion of the substrates. Recently we overcame this problem by the invention of nanocomposite catalysts composed of noble metal nanoclusters and inorganic semiconductor nanoparticles. Over these nanocomposite catalysts, the hydrodechlorination of ortho-chloroaniline was completely suppressed even at 100% conversion of ortho-chloronitrobenzene. In this review, we deal with the great efforts and remarkable contributions of different authors during the long exploration for the solutions of this hard obstacle. Stress is placed on supported metal catalysts and polymer-protected metal nanoclusters or colloid catalysts.
Export Options
About this article
Cite this article as:
Wang Xiaodong, Liang Minghui, Zhang Junling and Wang Yuan, Selective Hydrogenation of Aromatic Chloronitro Compounds, Current Organic Chemistry 2007; 11 (3) . https://dx.doi.org/10.2174/138527207779940856
DOI https://dx.doi.org/10.2174/138527207779940856 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Body Image Disturbance and Psychopathology in Children: Research Evidence and Implications for Prevention and Treatment
Current Psychiatry Reviews Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Current Alzheimer Research Sunscreening and Photosensitizing Properties of Coumarins and their Derivatives
Letters in Drug Design & Discovery Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Outcome Measures for Clinical Trials in Interstitial Lung Diseases
Current Respiratory Medicine Reviews Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Post-treatment with a Hydrogen Sulfide Donor Limits Neuronal Injury and Modulates Potassium Voltage-gated Channel Subfamily D Member 2 (Kv4.2) and Potassium Channel Interacting Protein 3 (KChIP3) During Transient Global Cerebral Ischemia
Current Neurovascular Research Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Technological Advances in Antigen Delivery and Synthetic Peptide Vaccine Developmental Strategies
Mini-Reviews in Medicinal Chemistry The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice
Current Medicinal Chemistry Hydrolytic Activity of Amyloid-beta and its Inhibition with Short Peptides
Current Medicinal Chemistry - Central Nervous System Agents Mesenchymal Stromal Cell Secretome: Immunomodulation, Tissue Repair and Effects on Neurodegenerative Conditions
Current Stem Cell Research & Therapy Status Epilepticus: An Overview
Current Drug Metabolism Development of Effective PET and SPECT Imaging Agents for the Serotonin Transporter: Has a Twenty-Year Journey Reached its Destination?
Current Topics in Medicinal Chemistry Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety Exploring the Evidence Implicating the Renin-Angiotensin System (RAS) in the Physiopathology of Mood Disorders
Protein & Peptide Letters Functionalization of the Carbonyl Group in Position 6 of Morphinan-6-ones. Development of Novel 6-Amino and 6-Guanidino Substituted 14-Alkoxymorphinans
Current Pharmaceutical Design